Evidence map›Paper›PMID 42851173›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026

[Chinese expert consensus on the diagnosis and treatment of pulmonary chronic graft-versus-host disease (2026)].

Chinese Society of Hematology, Chinese Medical Association, Chinese College of Chest Physicians, Chinese Medical Doctor Association, Leukemia Committee, Chinese Society of Clinical Oncology, Immunodeficiency Committee, Guangdong Provincial Association of Basic Medicine, Guangdong Respiratory and Health Association, Committee of Hematological Immunology Diagnosis and Treatment, Guangdong Medical Education Association

Abstract readConsensus StatementEnglish Abstract
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chinese Society of Hematology, Chinese Medical Association
Chinese College of Chest Physicians, Chinese Medical Doctor Association
Leukemia Committee, Chinese Society of Clinical Oncology
Immunodeficiency Committee, Guangdong Provincial Association of Basic Medicine
Guangdong Respiratory and Health Association
Committee of Hematological Immunology Diagnosis and Treatment, Guangdong Medical Education Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary chronic graft-versus-host disease (cGVHD) is a clinically significant complication after allogeneic hematopoietic stem cell transplantation, severely affecting the quality of life and survival rate of hematopoietic stem cell transplantation recipients. Bronchiolitis obliterans syndrome and interstitial lung diseases are the two main clinical entities. However, the insidious onset, diagnostic challenges, and limited therapeutic options of pulmonary cGVHD result in suboptimal clinical management and poor prognosis. Based on the latest developments in pulmonary cGVHD research and increasing evidence-based medicine data, this consensus was developed collaboratively by multidisciplinary experts domestically, providing recommendations for the early recognition, diagnosis, treatment, and management of pulmonary cGVHD, aiming to establish a standardized diagnostic and therapeutic workflow for pulmonary cGVHD applicable to clinical practice in China, to better guide clinical practice and improve patients' quality of life and survival rate.

Indexed as

Graft vs Host DiseaseLung DiseasesChinaChronic DiseaseHematopoietic Stem Cell TransplantationHumans

Identifiers

PMID42851173
PMCPMC13669439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.